How to Cite
Abstract
Type 2 Diabetes Mellitus (T2DM) is a chronic progressive metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction. It represents one of the most significant global health burdens of the 21st century. This paper examines the epidemiology, pathophysiology, clinical manifestations, complications, diagnostic criteria, and contemporary treatment approaches of T2DM. The study is structured according to the IMRAD format and integrates current evidence-based guidelines.
References
1. American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care, 47(Suppl.1).
2. World Health Organization. (2023). Global Report on Diabetes.
3. International Diabetes Federation. (2023). IDF Diabetes Atlas, 10th Edition.
4. Zinman B., et al. (2015). Empagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine.
5. Marso S.P., et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine.
6. Davies M.J., et al. (2018). Management of Hyperglycemia in Type 2 Diabetes. Diabetes Care.
7. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin. The Lancet.
This work is licensed under a Creative Commons Attribution 4.0 International License.